United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Stock Information for Evolve Transition Infrastructure LP representing Class B Limited Liability Company Interests

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evolve Transition Infrastructure LP representing Class B Limited Liability Company Interests

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
Mesoblast Participation at Piper Sandler Conference
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
James M. O'Brien Appointed Chief Financial Officer at Mesoblast
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
Mesabi Trust Press Release

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.